A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer

Journal of Clinical Oncology

Volumn 23, Issue 5, 2005, Pages 939-952

  Pietras, Kristian ^a   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SU 10944; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CARCINOGENESIS; CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; INSULINOMA; MONOTHERAPY; MOUSE; NEUROENDOCRINE TUMOR; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PERICYTE; PRIORITY JOURNAL; TRANSGENE; ANIMAL; APOPTOSIS; CLINICAL PROTOCOL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; REMISSION; TRANSGENIC MOUSE; VASCULARIZATION;

ADENOMA, ISLET CELL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; INDOLES; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PERICYTES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REMISSION INDUCTION;

EID: 14644446018     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.093     Document Type: Article

References (55)

1. Folkman J: Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 175:409-416, 1972
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
3. Inoue M, Hager JH, Ferrara N, et al: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193-202, 2002
4. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410, 2003
5. Cao Y: Antiangiogenic cancer therapy. Semin Cancer Biol 14:139-145, 2004
6. US National Cancer Institute: Angiogenesis Inhibitors in Clinical Trials, 3/03 update. http://www.cancer.gov/clinicaltrials/developments/anti-angio-table
7. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004
8. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
9. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
10. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047, 2000
11. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004
12. Gasparini G: Metronomic scheduling: The future of chemotherapy? Lancet Oncol 2:733-740, 2001
13. Bergers G, Hanahan D: Combining anti-angiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 67:293-300, 2002
14. Gerhardt H, Betsholtz C: Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314:15-23, 2003
15. Pietras K, Sjoblom T, Rubin K, et al: PDGF receptors as cancer drug targets. Cancer Cell 3:439-443, 2003
16. Lindahl P, Bostrom H, Karlsson L, et al: Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol 93:27-33, 1999
17. Abramsson A, Lindblom P, Betsholtz C: Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112:1142-1151, 2003
18. Lindblom P, Gerhardt H, Liebner S, et al: Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17:1835-1840, 2003
19. Furuhashi M, Sjoblom T, Abramsson A, et al: Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 64:2725-2733, 2004
20. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
21. Sundberg C, Kowanetz M, Brown LF, et al: Stable expression of angiopoietin-1 and other markers by cultured pericytes: Phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82:387-401, 2002
22. Gerhardt H, Wolburg H, Redies C: N-cadherin mediates pericytic- endothelial interaction during brain angiogenesis in the chicken. Dev Dyn 218:472-479, 2000
23. Hanahan D: Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122, 1985
24. Folkman J, Watson K, Ingber D, et al: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989
25. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
26. Erber R, Thurnher A, Katsen AD, et al: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340, 2004
27. Shaheen RM, Tseng WW, Davis DW, et al: Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61:1464-1468, 2001
28. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744, 2000
29. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
30. Parangi S, O'Reilly M, Christofori G, et al: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007, 1996
31. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
32. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits In vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
33. Patel N, Sun L, Moshinsky D, et al: A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther 306:838-845, 2003
34. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
35. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
36. Man S, Bocci G, Francia G, et al: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735, 2002
37. Pietras K, Rubin K, Sjöblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002
38. Pietras K: Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 31:18-23, 2004
39. Broxterman HJ, Lankelma J, Hoekman K: Resistance to cytotoxic and anti-angiogenic anticancer agents: Similarities and differences. Drug Resist Updat 6:111-127, 2003
40. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Investig Drugs 12:51-64, 2003
41. Motzer RJ, Rini BI, Michaelson MD, et al: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol 23:145, 2004 (abstr 4500)
42. Liu W, Reinmuth N, Stoeltzing O, et al: Antiangiogenic therapy targeting factors that enhance endothelial cell survival. Semin Oncol 29:96-103, 2002
43. Hirschi KK, Rohovsky SA, D'Amore PA: PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141:805-814, 1998
44. Lindahl P, Johansson BR, Levéen P, et al: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245, 1997
45. Soriano P: Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev 8:1888-1896, 1994
46. Sano H, Ueda Y, Takakura N, et al: Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endotnelial cells and disrupts glomerular capillary formation in neonatal mice. Am J Pathol 161:135-143, 2002
47. Ebnoether M, Stentoft J, Ford J, et al: Cerebral oedema as a possible complication of treatment with imatinib. Lancet 359:1751-1752, 2002
48. Esmaeli B, Prieto VG, Butler CE, et al: Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881-887, 2002
49. Jayson GC, Parker GJM, Mullamitha S, et al: Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973-981, 2005
50. Camitta BM, Kamen BA: Role of methotrexate in the treatment of acute lymphoblastic leukemia, In Pui CH (ed): Treatment of acute leukemias. Totowa, NJ, Humana Press Ltd, 2002
51. Emmenegger U, Man S, Shaked Y, et al: A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994-4000, 2004
52. Kakolyris S, Samonis G, Koukourakis M, et al: Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 21:505-508, 1998
53. Alvarez A, Mickiewicz E, Brosio C, et al: Weekly taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule. Proc Am Soc Clin Oncol 17:A188, 1998 (abstr 726)
54. Greco FA: Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 26:28-31, 1999
55. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000